BEAM
Beam Therapeutics Inc

6,223
Mkt Cap
$2.83B
Volume
2,309.00
52W High
$35.25
52W Low
$13.53
PE Ratio
-6.20
BEAM Fundamentals
Price
$27.96
Prev Close
$28.20
Open
$28.69
50D MA
$22.48
Beta
1.92
Avg. Volume
3M
EPS (Annual)
-$4.58
P/B
2.69
Rev/Employee
$131,507.25
Loading...
Loading...
News
all
press releases
Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks·7d ago
News Placeholder
More News
News Placeholder
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Zacks·7d ago
News Placeholder
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet
The mean of analysts' price targets for Beam Therapeutics (BEAM) points to a 76.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·10d ago
News Placeholder
Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?
Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.
Zacks·10d ago
News Placeholder
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Zacks·1mo ago
News Placeholder
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1mo ago
News Placeholder
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
Zacks·2mo ago
News Placeholder
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
Zacks·2mo ago
News Placeholder
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Zacks·2mo ago
News Placeholder
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
Zacks·3mo ago

Latest BEAM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.